+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Human hepatocellular carcinoma tissue lysate, Primary antibody: P09951(SLC26A3 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09951(SLC26A3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The SLC26A3 antibody is a tool used to detect and study the solute carrier family 26 member 3 (SLC26A3) protein, a chloride/bicarbonate exchanger primarily expressed in the apical membrane of intestinal and colonic epithelial cells. SLC26A3 plays a critical role in maintaining electrolyte and fluid homeostasis by mediating electroneutral Cl?/HCO?? exchange, essential for proper absorption of chloride and secretion of bicarbonate. Mutations in the SLC26A3 gene are linked to congenital chloride diarrhea (CLD), a rare autosomal recessive disorder characterized by severe chronic diarrhea and metabolic alkalosis.

The SLC26A3 antibody is widely utilized in biomedical research to investigate protein expression, localization, and function in normal and diseased tissues. It aids in diagnosing CLD through immunohistochemical analysis of intestinal biopsies, where reduced or absent staining correlates with pathogenic variants. Additionally, the antibody is employed in Western blotting, immunofluorescence, and flow cytometry to study SLC26A3 regulation in conditions like inflammatory bowel disease (IBD) or colorectal cancer, where its expression may be dysregulated. Commercial SLC26A3 antibodies are typically raised against specific epitopes, often validated for specificity using knockout controls or siRNA-based silencing. Understanding SLC26A3's role via antibody-based assays contributes to elucidating its pathophysiological mechanisms and potential therapeutic targeting.